Peptide Research Database

Access 7,487 peer-reviewed studies, clinical trials, and research papers on peptides. Filter by key research, study type, compound, and category. Direct links to full PubMed entries for comprehensive, evidence-based exploration.

Clinical Trial
Highly Cited
PMID: 43012507
2026 Nov 11

Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial.

In a randomized trial, these findings support concomitant IXE+TZP in patients with active PsA and immunometabolic disease. The objective of this report is to evaluate the effect of IXE+TZP versus IXE on psoriatic disease control and safety measures up to week 52.

Merola JF, Kartman CE, Fischer P, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D, Sun L, Chen Y, Marulkar K, Bello N, Cardoso A, Genovese MC, Ogdie A

Obesity or overweight occurs in 72% to 82% of individuals with psoriatic arthritis (PsA). Previous data revealed greater disease control with concomitant ixekizumab (IXE) and tirzepatide (TZP) versus IXE alone in adults with active PsA and obesity or overweight with at least one weight-related comorbidity at the week 36 primary end point. The objective of this report is to evaluate the effect of IXE+TZP versus IXE on psoriatic disease control and safety measures up to week 52. TOGETHER-PsA (ClinicalTrials.gov ID NCT06588296) is a phase 3b, randomized, open-label, assessor-blinded 52-week trial. Participants were randomized 1:1 to IXE+TZP or IXE using US-approved doses. Week 52 outcomes were prespecified, non-multiplicity-controlled, and exploratory. Outcomes included 50% improvement in American College of Rheumatology response criteria (ACR50) and rheumatologic, dermatologic, patient-reported, metabolic, and safety outcomes. A total of 271 participants were randomized (IXE+TZP, n = 138; IXE, n = 133). The proportion achieving the primary outcome of simultaneous ACR50 and ≥10% weight reduction continued to increase from week 36 through week 52 for IXE+TZP (39.2%) versus IXE (1.7%) (Δ37.5%; P < 0.001). ACR50 continued to diverge after week 36, with a clinically meaningful difference at week 52 for IXE+TZP (43.7%) versus IXE (15.7%) (Δ 28.0%; P < 0.001). IXE+TZP demonstrated significant improvements in ACR20, minimal disease activity, Disease Activity Index for Psoriatic Arthritis, patient-reported outcomes, and metabolic outcomes versus IXE alone. Safety profiles were consistent with previous studies for each drug. Comprehensive improvements in disease activity, including ACR50, quality of life, weight, and metabolic outcomes, continued through week 52 and were greater with IXE+TZP than IXE alone, with no new safety concerns. These findings support concomitant IXE+TZP in patients with active PsA and immunometabolic disease.

Arthritis &amp; rheumatology (Hoboken, N.J.)
Other
PMID: 43013893
2026 Nov 11

Detecting GHRH Analogue Tesamorelin and Its Metabolites in Post-Administration Human Urine and Serum Using LC-HRMS/MS.

In a clinical study, the outcome of this study shows that tesamorelin has a short detection window and testing methods should focus on metabolites in serum, rather than intact compounds in urine.

Colpaert T, Miller G, Goodrum J, Nair V, Crouch A, Van Eenoo P, Deventer K

Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue used for reducing excess abdominal fat in HIV-infected patients suffering from lipodystrophy. Together with other GHRH analogues, it is classified as a doping agent and is prohibited at all times according to the World Anti-Doping Agency (WADA). To investigate whether current testing methodologies are adequate for detecting tesamorelin abuse, an administration study was performed involving six healthy volunteers and 10 consecutive days of Egrifta (tesamorelin) injections, mimicking a doping protocol. A validated solid-phase extraction method was used to analyse the samples, reaching limits of detection of 13 pg/mL in urine and 41 pg/mL in serum. To account for the generation of metabolites by proteolytic degradation, tesamorelin was incubated in fresh human serum. Five previously unreported metabolites were found and identified, extending the detectability of tesamorelin abuse. Oxidation of the methionine residue was observed in tesamorelin and metabolites, hence ions to monitor the sulfoxide and sulfone forms were added to the methods. Despite a limit of detection 70 times lower than the WADA minimum required performance level and the inclusion of several metabolites, tesamorelin use could not be detected in post-administration urine. In serum, tesamorelin metabolites were detected in all six volunteers for up to 2 h after injection, whereas intact tesamorelin was detected in just two volunteers, up to 30 min post-administration. The outcome of this study shows that tesamorelin has a short detection window and testing methods should focus on metabolites in serum, rather than intact compounds in urine.

Drug testing and analysis
Other
PMID: 43016228
2026 Nov 11

Tirzepatide, Salivary Function, and Complete Dentures in Older Adults: Are we Overlooking the Denture-Saliva-Mucosa Interface?

Miranda DA, de Arruda JAA, de Andrade BAB

Oral diseases
Clinical Trial
Landmark Study
PMID: 43014326
2026 Nov 11

Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.

In a clinical trial, further study is required to understand whether improved body composition during weight loss might preserve physical function and overall metabolic health. The aim of this study was to evaluate the effect of antibodies blocking GDF8 (trevogrumab) and ActA (garetosmab) on semaglutide-induced weight and muscle loss.

Mosenzon O, Rosenstock J, Raya JG, Grimsby JS, Calle RA, Cannon K, Haggag AZ, Bays H, Sarkar N, Templeton A, Fanous M, Lighter J, Vavere A, Yancopoulos GD, Hirshberg B

Rapid weight loss, as induced by GLP-1 receptor agonists, is accompanied by pronounced muscle loss. GDF8 (myostatin) and activin A (ActA), acting via ActRIIA/B receptors, are negative regulators of muscle mass. The aim of this study was to evaluate the effect of antibodies blocking GDF8 (trevogrumab) and ActA (garetosmab) on semaglutide-induced weight and muscle loss. COURAGE is a two-part, phase 2, double-blind, placebo-controlled, randomised trial. This multicentre (60 sites), US-based trial enrolled participants aged 18-80 years with obesity (BMI ≥30 kg/m2). In part A, participants were treated for 26 weeks with semaglutide (titrated to 2·4 mg subcutaneously weekly) in addition to a randomly assigned (1:1:1:1) concomitant treatment: placebo, trevogrumab 200 mg, trevogrumab 400 mg, or trevogrumab 400 mg and garetosmab 10 mg/kg. Trevogrumab was administered subcutaneously weekly and garetosmab was administered intravenously every 4 weeks. Part A also included a subsequent semaglutide withdrawal period, at which point participants (randomly assigned at baseline 1:1 within each group) received either trevogrumab 400 mg or placebo for an additional 26 weeks. In part B, participants were treated with semaglutide for 52 weeks and randomly assigned (1:2:2) to concomitant treatment with placebo, trevogrumab 25 mg, or trevogrumab 75 mg. Groups were stratified according to sex, BMI (<35 kg/m2vs ≥35 kg/m2), and participation in an exploratory MRI substudy assessing thigh muscle volume. Study participants, the principal investigators, and study site personnel were masked to all randomisation assignments throughout the study. Primary endpoints were percent change in lean mass, fat mass, and bodyweight from baseline to week 26 (part A) or week 52 (part B). Efficacy and safety analyses were done in all randomly assigned participants who received at least one dose of a study drug (efficacy, as randomly assigned; safety, as treated). COURAGE is registered with ClinicalTrials.gov, NCT06299098, and is currently active, not recruiting. 975 participants were enrolled between June 21, 2024, and April 14, 2025. Mean age was 49·0 years (SD 13·2) and mean BMI was 36·7 kg/m2 (SD 5·0); 627 (64%) of 975 participants were female and 348 (36%) were male. In part A (n=605, of whom n=599 received at least one dose of study drug), a substantial decrease in lean mass was observed in the semaglutide plus placebo group at week 26 (-6·6% [95% CI -7·4 to -5·7]); the estimated treatment difference (ETD) versus semaglutide plus placebo was +3·1% (95% CI 1·9 to 4·3) with semaglutide plus trevogrumab 200 mg, +2·7% (1·5 to 4·0) with semaglutide plus trevogrumab 400 mg, and +4·5% (3·1 to 5·9) with semaglutide plus trevogrumab 400 mg plus garetosmab 10 mg/kg. In part B (n=376), lean mass percent change from baseline to week 52 for semaglutide plus placebo was -7·3% (-8·8 to -5·8); the ETD versus semaglutide plus placebo was +1·5% (-0·3 to 3·3) for semaglutide plus trevogrumab 25 mg, and +3·1% (1·3 to 4·9) for semaglutide plus trevogrumab 75 mg. Change from baseline in fat mass in part A was -15·6% (-17·4 to -13·9) in the semaglutide plus placebo group; the ETD was significant in the semaglutide plus trevogrumab 400 mg group (-3·4% [-5·9 to -0·9]) and the semaglutide plus trevogrumab 400 mg plus garetosmab 10 mg/kg group (-11·7% [-14·4 to -9·0]) in part A. No other groups in part A nor any in part B had significantly different changes in fat mass compared with semaglutide plus placebo. Percent change in bodyweight in part A was -10·6 (-11·6 to -9·7) in the semaglutide plus placebo group; the ETD was significant for the semaglutide plus trevogrumab 400 mg plus garetosmab 10 mg/kg group (-2·7 [-4·1 to -1·2]). No other groups in part A nor any in part B had significantly different changes in bodyweight compared with semaglutide plus placebo. Semaglutide plus trevogrumab (25 mg, 75 mg, 200 mg, or 400 mg) was generally well tolerated with a safety profile similar to semaglutide plus placebo; however, semaglutide plus trevogrumab 400 mg plus garetosmab 10 mg/kg had a high incidence of serious adverse events (14 [9%] of 149) and treatment discontinuations (48 [32%] of 149). Gastrointestinal adverse events were the most commonly reported, and they occurred with similar incidence across treatment groups. Muscle spasms occurred more frequently in the semaglutide plus trevogrumab 400 mg plus garetosmab 10 mg/kg group (61 [41%] of 149) compared with the semaglutide plus trevogrumab 200 mg or 400 mg groups (23 [8%] of 299) and semaglutide plus placebo groups (seven [5%] of 151). Most adverse events were mild to moderate in severity. Two deaths occurred during the study, both in the semaglutide plus trevogrumab 400 mg plus garetosmab 10 mg/kg group; a causal association between treatment and these events was not identified. This study establishes proof of concept for GDF8 inhibition by trevogrumab alone as a generally well tolerated strategy to preserve lean mass during GLP-1 receptor agonist-induced weight loss. Although the addition of ActA inhibition by garetosmab further improved body composition and weight loss, the combination did not have favourable safety and tolerability. Further study is required to understand whether improved body composition during weight loss might preserve physical function and overall metabolic health. Regeneron Pharmaceuticals, Inc.

Lancet (London, England)
Animal Study
DOI
2026-11-11

Sensory context gates oxytocin effects on auditory processing in macaques

In an animal study, together, these findings suggest that oxytocin modulates sensory response magnitude and inter-regional coordination in a context-dependent manner rather than uniformly enhancing social signals.

Froesel M, Wang H, Vanduffel W, Zhu Q.

Abstract / Summary Oxytocin shapes social perception, yet its neural effects vary substantially across experiments and clinical trials yield inconsistent results. A key unresolved question is whether oxytocin modulates early sensory processing in primates as a function of sensory context. Using high-resolution pharmacological fMRI in two awake rhesus macaques, we compared systemic oxytocin with saline during unimodal auditory and audiovisual tasks. During unimodal auditory stimulation, oxytocin attenuated sound-evoked responses throughout auditory core, belt and associative regions for both vocal and non-vocal sounds, while distributed sound-category information remained decodable. In contrast, when the same vocalizations were presented within an audiovisual task, this attenuation disappeared and responses increased in a restricted set of auditory core and belt regions. Oxytocin also reorganized resting-state coupling among auditory, visual and prefrontal systems and changed how evoked responses covaried across runs. Together, these findings suggest that oxytocin modulates sensory response magnitude and inter-regional coordination in a context-dependent manner rather than uniformly enhancing social signals.

Other
PMID: 43009514
2026 Nov 10

Gut microbiota-CRAMP axis controls salivary gland immune homeostasis in Sjögren's disease.

In a mouse study, by combining RNA sequencing with pharmacological inhibitors, we demonstrated that CRAMP acts through formyl peptide receptor 2 (FPR2) to inhibit the PI3K/AKT signaling pathway, thereby reducing the autoimmune response in the salivary glands.

Liang WJ, Zou HM, Chen XY, Fu XM, Wang J, Rebhi F, Nocturne G, Mariette X, Pan LL, Diana J, Sun J

Sjögren's disease (SjD) is a systemic autoimmune disorder marked by lymphocytic infiltration of exocrine glands. To date, its pathogenesis remains incompletely understood. Cathelicidins are a widespread family of host-defense antimicrobial peptides, primarily recognized for their antimicrobial properties, and are now increasingly appreciated for their immunomodulatory functions. However, the role of cathelicidin in the immunopathogenesis of SjD remains unknown. In this study, we investigated the effects of cathelicidin-related antimicrobial peptide (CRAMP) on SjD and the underlying mechanisms. Salivary gland tissues from SjD patients and controls were collected. Two established mouse models of SjD, i.e., the non-obese diabetic (NOD) mice that spontaneously develop SjD-like disease features, and salivary gland protein-induced experimental SjD mice, were used for the studies. Our data showed that salivary gland acinar cells produce cathelicidin, and that production is impaired in both SjD patients and mice compared to the control group. Moreover, CRAMP plays a protective role in SjD, as exogenous CRAMP administration improved the SjD phenotype, whereas CRAMP knockdown exacerbated disease severity. By combining RNA sequencing with pharmacological inhibitors, we demonstrated that CRAMP acts through formyl peptide receptor 2 (FPR2) to inhibit the PI3K/AKT signaling pathway, thereby reducing the autoimmune response in the salivary glands. Furthermore, we identified gut microbiota and its metabolite, propionic acid, as critical regulators of CRAMP expression in salivary gland acinar cells. Treatment with propionic acid or transfer of gut microbiota from a non-autoimmune control strain to SjD mice increased CRAMP levels and alleviated disease severity, highlighting a pivotal gut-salivary gland axis in SjD pathogenesis. Overall, these findings underscore the pivotal role of CRAMP in protecting against SjD and pave the way for future microbiota-based therapies.

Acta pharmacologica Sinica
Clinical Trial
Highly Cited
DOI
2026-11-10

Investigational Study of an NVG-291-Designated Peptide with Thymosin Beta-4 (TB-4) in Complete Spinal Cord Injury: Clinical Outcomes Over a 12-Month Follow-Up

In a randomized trial, these findings support further evaluation in larger, prospectively registered, randomized trials. Objective: To evaluate 12-month motor and functional outcomes of the investigator-initiated NuRaX combination protocol (NVG-291 plus TB-4) compared with placebo, each added to conservative rehabilitation.

Majumdar P, Lavrov I, Ahemad N, Ismayilzada R, Alam M, Matis G, Fenoy AJ, Jafarova U.

Background: Restoring useful motor function remains a major unmet need after complete spinal cord injury (SCI). A PTPσ-targeting peptide designated NVG-291, which relieves proteoglycan-mediated inhibition of axonal growth, and thymosin beta-4 (TB-4), which has cytoprotective and anti-inflammatory actions, offer complementary mechanisms that may enhance the response to rehabilitation. Objective: To evaluate 12-month motor and functional outcomes of the investigator-initiated NuRaX combination protocol (NVG-291 plus TB-4) compared with placebo, each added to conservative rehabilitation. Methods: In this single-center, randomized, double-blind, placebo-controlled study conducted at the NuRaX Center in partnership with Ege Hospital in Baku, Azerbaijan, 30 participants with complete (AIS A) SCI were assigned in a 1:1 ratio to the combination protocol (n = 15) or saline placebo (n = 15). Combination treatment comprised NVG-291 2.5 mg and TB-4 1.5 mg subcutaneously every 14 days for 12 months (cumulative 65 mg and 39 mg, respectively), plus a single 3.5 mg paraspinal NVG-291 dose at the T11–T12 vertebral level; placebo injections were matched in volume, route and timing. Both groups received the same rehabilitation program without stimulation or robotic equipment. Outcomes included lower extremity motor score (LEMS), walker-supported standing duration and 100-m walking completion without orthoses or physical assistance. All assessments were independently re-screened by blinded external consultants. Results: Mean LEMS increased by 7.6 points with combination treatment and by 0.6 points with placebo (between-group difference, 7.0 points; 95% CI, 4.8 to 9.2); the baseline-adjusted difference was 7.39 points (95% CI, 5.86 to 8.92). Standing duration increased by 4.01 minutes more with combination treatment (95% CI, 2.37 to 5.65). At 12 months, 13 of 15 combination participants (86.7%) and 1 of 15 placebo participants (6.7%) completed 100 m with a walker, without orthoses or physical assistance. No AIS grade conversion or change in bladder or bowel function was reported. No adverse events or injection-site reactions were documented. Conclusions: In participants with complete SCI, the NuRaX combination of NVG-291 and TB-4 added to conservative rehabilitation was associated with greater improvement in lower-limb motor scores, standing endurance and walker-supported walking than placebo with the same rehabilitation over 12 months. These findings support further evaluation in larger, prospectively registered, randomized trials.

Other
PMID: 43006658
2026 Nov 10

Response to: Mechanistic Plausibility Should Not Be Conflated With Clinical Validation of GHK-Cu.

Mokhtar J, Lellouch AG

Aesthetic surgery journal
Other
PMID: 43025349
2026 Nov 10

Evaluation of semaglutide in an ex vivo human placental perfusion model to estimate maternal-fetal transfer.

This study found these findings suggest limited placental passage during term gestation and offer guidance for decision making regarding semaglutide use during pregnancy.

Chan E, Zabek M, Balluku A, Garcia-Bournissen F, Hutson JR

Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used in females of reproductive age for glycemic control and weight management, with emerging evidence suggesting benefits on fertility and obstetrical outcomes. However, pregnancy safety data remain limited, and current guidance advises discontinuation before conception due to uncertain fetal exposure risk. Since many pregnancies are unplanned, inadvertent exposures are inevitable-further data is needed to inform clinical counselling and risk assessment. This study aims to determine whether semaglutide crosses the human placenta using an ex vivo dual-perfused cotyledon model. Transplacental transfer of semaglutide was assessed at clinically relevant (222 ng/mL, n = 4) or at ten-fold higher (2220 ng/mL, n = 4) concentrations. Each perfusion included a 1-h control period followed by a 3-h experimental period with drug exposure. Perfusates samples were collected over time to measure semaglutide concentrations and quality control markers. Semaglutide was quantified via a validated enzyme-linked immunosorbent assay kit. Paired Student's t-tests were used, with significance defined as p < 0.05. Placental viability was maintained throughout, supported by stable metabolic parameters and appropriate antipyrine transfer, confirming intact and functional cotyledons. Maternal semaglutide concentrations remained stable over the 180-min perfusion period in both conditions, with no significant time-dependent changes (p > 0.05). Fetal perfusate concentrations were all below the lower limit of quantification. Semaglutide demonstrated minimal-to-no detectable transfer across the term human placenta, even at supratherapeutic concentrations. These findings suggest limited placental passage during term gestation and offer guidance for decision making regarding semaglutide use during pregnancy.

Other
PMID: 43009382
2026 Nov 10

Temporal dynamics and prognostic value of serum calcitonin during tirzepatide therapy in adults with obesity.

This study found early calcitonin changes were associated with subsequent biochemical behavior, but the limited follow-up and small number of threshold events preclude conclusions regarding prognostic cutoffs or monitoring strategies.

Angelopoulos N, Simeakis G, Androulakis I, Rizoulis A, Boniakos A, Mentzelopoulou P, Korakovouni A, Zianni D, Petkova V, Livadas S, Paparodis R

To characterize serum calcitonin dynamics during six months of tirzepatide therapy for obesity and explore whether early changes are associated with subsequent biochemical behavior. This prospective observational study enrolled 77 adults with obesity initiating tirzepatide. One participant diagnosed with medullary thyroid carcinoma at baseline was excluded, leaving 76 participants for longitudinal analysis. Serum calcitonin was assessed at baseline, 3 months, and 6 months. Longitudinal changes were evaluated using non-parametric tests and mixed-effects models; prognostic analyses were exploratory. Median calcitonin increased modestly from 2.05 pg/mL at baseline to 2.12 pg/mL at 3 months and 2.25 pg/mL at 6 months, with a significant overall time effect (p < 0.001) but no further significant change between 3 and 6 months (p = 0.43). Two participants with baseline calcitonin < 12 pg/mL developed new-onset elevations ≥ 12 pg/mL during early follow-up; no additional cases occurred at 6 months. Early calcitonin change was strongly associated with six-month change (Spearman ρ=0.73, p < 0.001), although prognostic analyses were limited by only two threshold events. Median weight loss was 8.3% and 15.0% at 3 and 6 months, respectively. Tirzepatide was associated with a small early increase in serum calcitonin followed by stabilization through six months. Early calcitonin changes were associated with subsequent biochemical behavior, but the limited follow-up and small number of threshold events preclude conclusions regarding prognostic cutoffs or monitoring strategies.

Obesity research &amp; clinical practice